University of Aarhus · Interventional, Randomized
The present study is testing spermidine treatment in elderly patients with coronary artery disease. The study is a randomized, double-blind, placebo-controlled, two-armed, parallel-group, single centre, clinical study.
Full record on ClinicalTrials.gov (NCT ID NCT06186102).
| Endpoint | Type | Result | Significance |
|---|---|---|---|
| Change in left ventricular mass | Primary | None | None |
| Change in appendicular lean mass and ALM index | Primary | None | None |
| Change in High-sensitivity C-reactive Protein (hs-CRP) | Primary | None | None |
| Change in Physical performance, peak oxygen consumption (VO2max) | Primary | None | None |
| Muscle strength, Handgrip strength | Secondary | None | None |
| Muscle strength, Knee-extension/flexion strength | Secondary | None | None |
| Physical performance, 6 minute walk test (6MWT) | Secondary | None | None |
| Physical performance, 30 seconds sit to stand test | Secondary | None | None |
| The Short Physical Performance Battery | Secondary | None | None |
| Skeletal muscle mass | Secondary | None | None |
| Skeletal muscle cross sectional area (CSA) of fibers | Secondary | None | None |
| Skeletal muscle tissue fiber composition | Secondary | None | None |
| Skeletal muscle tissue cellular composition | Secondary | None | None |
| Skeletal muscle mitochondrial function | Secondary | None | None |
| Total lean body mass | Secondary | None | None |
| Total body fat percentage | Secondary | None | None |
| Estimated visceral adipose tissue | Secondary | None | None |
| Intramuscular and intermuscular fat content | Secondary | None | None |
| Free fatty acids | Secondary | None | None |
| Insulin resistance | Secondary | None | None |
| Markers of autophagy | Secondary | None | None |
| Polyamine content in muscle biopsy | Secondary | None | None |
| Polyamine content in blood | Secondary | None | None |
| Change in 24-hour ambulatory blood pressure measurements (24h ABPM) | Secondary | None | None |
| Change in central blood pressure | Secondary | None | None |
| Change in daily physical activity | Secondary | None | None |
| Change in cardiac extracellular volume fraction | Secondary | None | None |
| Change in myocardial strain | Secondary | None | None |
| Change in Carotid-femoral pulse wave velocity | Secondary | None | None |
| Change in Aortic pulse wave velocity | Secondary | None | None |
| Change in general cognitive function and memory performance | Secondary | None | None |
| Change in specific domains of cognitive function | Secondary | None | None |
| HeartQol | Secondary | None | None |
| Cytokines | Secondary | None | None |
| White blood cells | Secondary | None | None |
| Immune cells | Secondary | None | None |
| Vascular inflammatory markers | Secondary | None | None |
| Time to first occurrence of Composite cardiovascular endpoint: Cardiovascular death, heart failure hospitalizations, non-fatal myocardial infarction, non-fatal stroke, and coronary revascularization | Secondary | None | None |
| Days alive and out of hospital | Secondary | None | None |
Full results record on ClinicalTrials.gov.
Age range: 65–90 · Sex: All · Healthy volunteers: Requires diagnosis
1 site participated during the trial period. Representative sites shown below; full historical record on ClinicalTrials.gov.